Lamotrigine

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 37, Issue , 2012, Pages 245-285

  Beattie, Kevin ^a   Phadke, Geeta ^a   Novakovic, Jasmina ^a  

^a Apotex Inc   (Canada)

Author keywords

ADME; Analysis; Degradation; Impurities; Lamotrigine; Metabolism; Pharmacokinetics; Phenyltriazine anticonvulsant; Physical characteristics; Spectroscopy; Stability; Synthesis

Indexed keywords

LAMOTRIGINE;

ANTICONVULSANT THERAPY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROCHEMICAL ANALYSIS; FOCAL EPILEPSY; GRAND MAL SEIZURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; MICROEMULSION ELECTROKINETIC CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLANAR CHROMATOGRAPHY; POTENTIOMETRIC TITRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPECTROFLUOROMETRY; SPECTROPHOTOMETRY; SPECTROSCOPY; TABLET; THERMOGRAVIMETRY; THERMOSTABILITY; ULTRAVIOLET SPECTROSCOPY; WETTABILITY; X RAY DIFFRACTION;

EID: 84858611149     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397220-0.00006-4     Document Type: Chapter

References (94)

1. The Merck Index (online), 14th ed., Merck & Co. Inc., Whitehouse Station, NJ., Search Term: Lamotrigine, accessed on: Nov. 2, 2011. http://www.medicinescomplete.com/.
2. Zufia L., et al. LC method for the therapeutic drug monitoring of lamotrigine: evaluation of the assay performance and validation of its application in the route area. J. Pharm. Biomed. Anal. 2009, 49:547-553.
3. Hanna M., et al. 2009, WO 2009/061513 A1,.
4. Floyd A.G., Jain S. 1999, US 5,942,510,.
5. 2011, European Pharmacopoeia 7.0, vol. 2, Lamotrigine Monograph.
6. Shinde V.R., et al. Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique. J. Pharm. Pharmacol. 2008, 60:1121-1129.
7. Shayanfar A., et al. Solubility of clonazepam, diazepam, lamotrigine, and phenobarbital in n-methyl-2-pyrrolidone + water mixtures at 298.2 K. J. Chem. Eng. Data 2009, 54:2964-2966.
8. Soltanpour S., et al. Effects of different concentrations of poly(vinyl pyrrolidone) on the solubility of lamotrigine and diazepam in ethanol + water mixtures at 298.2 K. J. Chem. Eng. Data 2010, 55:570-573.
9. Soltanpour S., Jouyban A. Solubility of lamotrigine and diazepam in propylene glycol + water + carboxymethyl cellulose at a temperature of 298.2 K. J. Chem. Eng. Data 2010, 55:2890-2893.
10. 2008, ACD Labs, Release 11.00, Product Version 11.02, Build 25941, May 21,.
11. Sridhar B., Ravikumar K. Lamotrigine, an antiepileptic drug, and its chloride and nitrate salts. Acta Crystallogr. C 2009, C65:o460-o464.
12. Murthy K. 2005, MX PA04006216 A,.
13. Kishore C. 2005, WO 2005/003104 A2,.
14. Garti N., et al. 2008, US 2008/0139808 A1,.
15. Garti N., et al. 2002, WO 02/068398 A1,.
16. 2011, United States Pharmacopeia, 34 Revision. National Formulary 29th ed., Lamotrigine Monograph,.
17. Hosseini M., et al. Solubility analysis of clozapine and lamotrigine in supercritical carbon dioxide using static system. J. Supercrit. Fluids 2010, 52:30-35.
18. Edmeades L.M. 1999, EP 0 963 980 A2,.
19. 2011, British Pharmacopoeia, vol. 2, Lamotrigine Monograph,.
20. Burgoa Calvo M.E., et al. Determination of lamotrigine by adsorptive stripping voltammetry using silver nanoparticle-modified carbon screen-printed electrodes. Talanta 2007, 74:59-64.
21. Burgoa Calvo M.E., et al. Optimization of the experimental parameters in the determination of lamotrigine by adsorptive stripping voltammetry. Anal. Chim. Acta 2005, 549:74-80.
22. Altria K.D. Application of microemulsion electrokinetic chromatography to the analysis of a wide range of pharmaceuticals and excipients. J. Chromatogr. A 1999, 844:371-386.
23. El-Enany N.M., et al. Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde. J. Fluoresc. 2010, 20:463-472.
24. Youssef N.F., Taha E.A. Development and validation of spectrophotometric, TLC and HPLC methods for the determination of lamotrigine in presence of its impurity. Chem. Pharm. Bull. 2007, 55:541-545.
25. Dreassi E., et al. Quantitative analysis of lamotrigine in plasma and tablets by planar chromatography and comparison with liquid chromatography and UV spectrophotometry. J. AOAC Int. 1996, 79:1277-1280.
26. Ram V.R., et al. Development and validation of a stability indicating HPLC assay method for determination of lamotrigine in tablet formulation. Der Chemica Sinica 2011, 2:58-65.
27. Ferrer I., Thurman E.M. Identification of a new antidepressant and its glucuronide metabolite in water samples Using liquid chromatography/quadrupole time-of-flight mass spectrometry. Anal. Chem. 2010, 82:8161-8168.
28. Papadoyannis I.N., et al. Solid-phase extraction study and RP-HPLC Analysis of lamotrigine in human biological fluids and in antiepileptic tablet formulations. J. Liq. Chromatogr. 1995, 18:2593-2609.
29. Sinz M.W., Remmel R.P. Analysis of lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reversed-phase ion-pairing liquid chromatography. J. Chromatogr. 1991, 571:217-230.
30. Ramachandran S., et al. Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin and carbamazepine using reversed-phase high-performance liquid chromatography at dual wavelengths. Ther. Drug Monit. 1994, 16:75-82.
31. Yamashita S., et al. Simple and rapid analysis of lamotrigine, a novel antiepileptic, in human serum by high-performance liquid chromatography using a solid-phase extraction technique. J. Chromatogr. B 1995, 670:354-357.
32. Forssblad E., et al. Liquid chromatographic determination of plasma lamotrigine in pediatric samples. J. Pharm. Biomed. Anal. 1996, 14:755-758.
33. Hart A.P., et al. A rapid cost-effective high-performance liquid chromatographic (HPLC) assay of serum lamotrigine after liquid-liquid extraction and using HPLC conditions routinely used for analysis of barbiturates. Ther. Drug Monit. 1997, 19:431-435.
34. Ren S., et al. Determination of lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. Ther. Drug Monit. 1998, 20:209-214.
35. Matar K.M., et al. A rapid liquid chromatographic method for the determination of lamotrigine in plasma. J. Pharm. Biomed. Anal. 1998, 17:525-531.
36. Matar K.M., et al. Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma. Ther. Drug Monit. 1999, 21:559-566.
37. Torra M., et al. Optimized procedure for lamotrigine analysis in serum by high-performance liquid chromatography without interferences from other frequently coadministered anticonvulsants. Ther. Drug Monit. 2000, 22:621-625.
38. Khoschsorur G.A., et al. Simple and rapid HPLC method for simultaneous determination of multiple antiepileptic drugs in human serum. Chromatographia 2001, 54:345-349.
39. Castel-Branco M.M., et al. Lamotrigine analysis in blood and brain by high-performance liquid chromatography. J. Chromatogr. B 2001, 755:119-127.
40. Queiroz M.E.C., et al. Solid-phase microextraction-liquid chromatography (SPME-LC) determination of lamotrigine simultaneously with carbamazepine and carbamazepine 10,11-epoxide in human plasma. J. Sep. Sci. 2002, 25:91-95.
41. Contin M., et al. Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J. Chromatogr. B 2005, 828:113-117.
42. Vermeij T.A.C., Edelbroek P.M. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J. Chromatogr. B 2007, 857:40-46.
43. Bompadre S., et al. Determination of lamotrigine in whole blood with on line solid phase extraction. J. Chromatogr. B 2008, 863:177-180.
44. Fraser A.D. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther. Drug Monit. 1995, 17:174-178.
45. Angelis-Stoforidis P., et al. Determination of lamotrigine in human plasma by high-performance liquid chromatography. J. Chromatogr. B 1999, 727:113-118.
46. Saracino M.A., et al. Rapid HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma. J. Sep. Sci. 2007, 30:2249-2255.
47. Greiner-Sosanko E., et al. Simultaneous determination of lamtrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 2007, 21:225-228.
48. Greiner C., Haen E. Development of a simple column-switching high-performance liquid chromatograph (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine and 10-monohydroxycarbazepine (MHD). J. Chromatogr. B 2007, 854:338-344.
49. Fazio A., et al. A liquid chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma. Ther. Drug Monit. 1992, 14:509-512.
50. Sallustio B.C., Morris R.G. High-performance liquid chromatography quantitation of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy. Ther. Drug Monit. 1997, 19:688-693.
51. Bartoli A., et al. A rapid and specific assay for the determination of lamotrigine in human plasma by normal-phase HPLC. Ther. Drug Monit. 1997, 19:100-107.
52. Cheng C.L., et al. Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. J. Chromatogr. B 2005, 817:199-206.
53. Cociglio M., et al. Performance analysis of a reversed-phase liquid chromatographic assay of lamotrigine in plasma using solvent-demixing extraction. J. Chromatogr. 1991, 572:269-276.
54. Meyler M., et al. New method for the determination of four antiepileptic drugs in human plasma by high performance liquid chromatography. Chromatographia 1993, 36:27-32.
55. Lensmeyer G.L., et al. Optimized high-performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine and carbamazepine epoxide. Ther. Drug Monit. 1997, 19:292-300.
56. Franceschi L., Furlanut M. A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. Pharmacol. Res. 2005, 51:297-302.
57. Londero D., Greco P.L. New micromethod for the determination of lamotrigine in human plasma by high-performance liquid chromatography. J. Chromatogr. B 1997, 691:139-144.
58. Croci D., et al. New high-performance liquid chromatographic method for plasma/serum analysis of lamotrigine. Ther. Drug Monit. 2001, 23:665-668.
59. Heideloff C., et al. A novel HPLC method for quantification of 10 antiepileptic drugs or metabolites in serum/plasma using a monolithic column. Ther. Drug Monit. 2010, 32:102-106.
60. Doig M.V., Clare R.A. Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J. Chromatogr. 1991, 554:181-189.
61. Beck O., et al. Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther. Drug Monit. 2006, 28:603-607.
62. Sorensen L.K. Determination of acidic and neutral therapeutic drugs in human blood by liquid chromatography-electrospray tandem mass spectrometry. Forensic Sci. Int. 2011, 206:119-126.
63. Shah H.J., et al. Rapid quantification of lamotrigine in human plasma by two LC systems connected with tandem MS. J. Chromatogr. Sci. 2010, 48:375-381.
64. Lee W., et al. Determination of lamotrigine in human serum by high-performance liquid chromatography-tandem mass spectrometry. Neurol. Sci. 2010, 31:717-720.
65. Queiroz M.E.C., et al. Determination of lamotrigine simultaneously with carbamazepine, carbamazepine epoxide, phenytoin, phenobarbital, and primidone in human plasma by SPME-GC-TSD. J. Chromatogr. Sci. 2002, 40:219-223.
66. Watelle M., et al. Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatograph with nitrogen phosphorus detection. Ther. Drug Monit. 1997, 19:460-464.
67. Dasgupta A., Hart A.P. Lamotrigine analysis in plasma by gas chromatography-mass spectrometry after conversion to a tert-butyldimethylsilyl derivative. J. Chromatogr. B 1997, 693:101-107.
68. Hallbach J., et al. Determination of lamotrigine, carbamazepine and carbamazepine epoxide in human serum by gas chromatography mass spectrometry. Eur. J. Clin. Chem. Clin. Biochem. 1997, 35:755-759.
69. Patil K.M., Bodhankar S.L. High-performance thin-layer chromatographic determination of lamotrigine in serum. J. Chromatogr. B 2005, 823:152-157.
70. Shihabi Z.K., Oles K.S. Serum lamotrigine analysis by capillary electrophoresis. J. Chromatogr. B 1996, 683:119-123.
71. Theurillat R., et al. Therapeutic drug monitoring of lamotrigine using capillary electrophoresis. Evaluation of assay performance and quality assurance over a 4-year period in the routine arena. J. Chromatogr. A 2002, 979:353-368.
72. Zheng J., et al. Development of capillary zone electrophoresis-electrospray ionization-mass spectrometry for the determination of lamotrigine in human plasma. Electrophoresis 2004, 25:2033-2043.
73. Pucci V., et al. Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography. Electrophoresis 2005, 26:935-942.
74. Biddlecombe R.A., et al. Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine. J. Pharm. Biomed. Anal. 1990, 8:691-694.
75. Sailstad J.M., Findlay J.W. Immunofluorometric assay for lamotrigine (Lamictal) in human plasma. Ther. Drug Monit. 1991, 13:433-442.
76. Coulter D.A. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in?. J. Child Neurol. 1997, 12:S2-S9.
77. Goa K.L., et al. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993, 46:152-176.
78. Fitton A., Goa K.L. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995, 50:691-713.
79. Burstein A.H. Evaluation of new drugs: lamotrigine. Pharmacotherapy 1995, 15:129-143.
80. Rambeck B., Wolf P. Lamotrigine clinical pharmacokinetics. Clin. Pharmacokinet. 1993, 25:433-443.
81. Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin. Drug Metab. Toxicol. 2006, 2:1009-1018.
82. Garnett W.R. Lamotrigine: pharmacokinetics. J. Child Neurol. 1997, 12:S10-S15.
83. Yuen W.C., Peck W. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br. J. Clin. Pharmacol. 1988, 26:242P.
84. Peck A.W. Clinical pharmacology of lamotrigine. Epilepsia 1991, 32:S9-S12.
85. Cohen A.F., et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 1987, 42:534-541.
86. ® ) in patients with epilepsy. Epilepsy Res. 1991, 10:191-200.
87. Jawad S. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res. 1987, 1:194-201.
88. Arif H., et al. The effect of age and comedication on lamotrigine clearance tolerability, and efficacy. Epilepsia 2011, 52:1905-1913.
89. Posner J., et al. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br. J. Clin. Pharmacol. 1989, 28:117-120.
90. Yuen A.W., et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Pharmacol. 1992, 33:511-513.
91. Winter R.G., et al. 1999, US 5,912,345,.
92. Qian Y., et al. Synthesis, antimicrobial activity of lamotrigine and its ammonium derivatives. J. Chem. Sci. 2009, 121:463-470.
93. G. Lee, WO 96/20935.
94. Schneider G., et al. 2003, US 2003/0191310 A1,.